Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide

Authors Li C, WANG Y, ZHANG X, DENG L, Zhang Y, Chen Z

Received 19 November 2012

Accepted for publication 10 January 2013

Published 12 March 2013 Volume 2013:8(1) Pages 1051—1062


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Chong Li,1,2 Yixin Wang,3 Xiaolin Zhang,1 Li Deng,1 Yan Zhang,1 Zhangbao Chen1

1Key Laboratory on Luminescence and Real-Time Analysis, Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, People's Republic of China; 2School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA, Fudan University, Shanghai, People's Republic of China; 3Department of Pharmacy, the Second People's Hospital of Sichuan Province and Sichuan Cancer Hospital, Chengdu, People's Republic of China

Abstract: Peptide ligands have played an important role in tumor-targeted drug delivery as targeting moieties. The in vivo fate of peptide-mediated drug delivery systems and the following antitumor effects may greatly depend on the stability of the peptide ligand. In the current study, a tumor-targeting cyclic peptide screened by phage display, Lyp-1 (a peptide that specifically binds to tumor and endothelial cells of tumor lymphatics in certain tumors), was structurally modified by replacement of the original intramolecular disulfide bond with a diseleno bond. The produced analog Syp-1 (seleno derivative of Lyp-1) maintained specific binding ability to the target protein p32 (Kd = 18.54 nM), which is similar to that of Lyp-1 (Kd = 10.59 nM), indicated by surface plasmon resonance assay. Compared with Lyp-1, Syp-1 showed significantly improved stability against serum. After the peptide attached onto the surface of fluorophore-encapsulating liposomes, the more efficient tumor uptake of liposomal fluorophore mediated by Syp-1 was observed. Furthermore, Syp-1 modified liposomal doxorubicin presented the most potent tumor growth inhibitory ability among all the therapeutic groups, with a low half maximal inhibitory concentration of 588 nM against MDA-MB-435 cells in vitro and a high tumor inhibition rate of 73.5% in vivo. These findings clearly indicated that Syp-1 was a stable and effective tumor targeting ligand and suggest that the sulfur-to-selenium replacement strategy may help stabilize the phage-displayed cyclic peptide containing disulfide-bond under physiological conditions and strongly support the validity of peptide-mediated drug targeting.

Keywords: tumor targeting, liposome, cyclic peptide, selenopeptide

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.